Abpro(NASDAQ) ABP

Abpro develops antibody medicines for cancer and eye diseases. Its products aim to help patients with hard-to-treat conditions. The company uses new technology to create targeted treatments for specific medical needs.

Antibodies in Action: What Abpro Sells

• ABP-102 (Cancer Therapy): Tetravalent antibody for breast and gastric cancers; no revenue contribution yet.
• ABP-201 (Eye Disease): Tetravalent antibody for wet age-related macular degeneration; not yet commercialized.
• Pipeline Programs: Includes ABP-100, ABP-110, ABP-150, and a COVID-19 antibody; all pre-commercial.
• Collaborative Projects: Joint research with partners for new antibody drugs; no product sales to date.

Growth Spurts and Strategic Moves

• Completed merger with Atlantic Coastal Acquisition Corp. II in November 2024, leading to Nasdaq listing.
• Formed partnerships with NJCTTQ, Abpro Bio Co. Ltd, Celltrion, and others for research and licensing.
• Raised $11.2 million through PIPE financing in November 2024 to support operations.
• Expanded product pipeline with new antibody candidates between 2023 and 2025.

Why Abpro Stands Out (Without the Lab Coat)

Abpro uses proprietary technology to design antibodies that target two disease markers at once. Its focus on rare and hard-to-treat diseases sets it apart from many peers. The company relies on global partnerships to advance its research and share development risks.

Five Things You Need to Know

• Revenue was $0 in Q2 2025, unchanged from Q2 2024.
• Operating loss was approximately $2.3 million in Q2 2025, down 3.4% year-on-year.
• Cash and restricted cash totaled $2 million as of June 30, 2025.
• Research and development expenses fell 62% year-on-year in Q2 2025.
• Accumulated deficit reached $123 million by June 30, 2025.

Bottom Line

Abpro remains focused on developing new antibody drugs for serious diseases. The company faces financial challenges but continues to pursue innovation through partnerships and technology.